Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation

NCT03398434 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Trial cancelled before First Patient First Visit (no patient enrolled)

Conditions

Atrial Fibrillation

Interventions

DRUG: MAA868
DRUG: Apixaban

Sponsor

Novartis Pharmaceuticals